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The Food and Drug Administration issued guidance for evaluating the cardiovascular risk of new diabetes mellitus drugs in 2008. Accumulating
evidence from several completed trials conducted within this framework raises questions as to whether requiring safety outcome studies for all
new diabetes mellitus therapies remains justified. Given the burden of cardiovascular disease in patients with diabetes, the focus should shift
towards cardiovascular outcome studies designed to evaluate efficacy (i.e. to determine the efficacy of a drug over placebo or standard care)
rather than demonstrating that risk is not increased by a pre-specified safety margin. All stakeholders are responsible for ensuring that new drug
approvals occur under conditions of appropriate safety and effectiveness. It is also a shared responsibility to avoid unnecessary hurdles that may
compromise access to useful drugs and threaten the sustainability of health systems. It is critical to renew this debate so that stakeholders can
collectively determine the optimal approach for developing new drugs to treat type 2 diabetes mellitus.
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Introduction
The US Food and Drug Administration (FDA) issued an Industry
Guidance in 2008 for evaluating the cardiovascular safety of new
therapies for the treatment of patients with type 2 diabetes mellitus.
The guidance was developed in response to concerns about the
cardiovascular safety of these drugs, which originated with rosiglita-
zone.1 This guidance shifted the focus of diabetes research towards
clinical trials designed to evaluate cardiovascular safety. Briefly, for
each drug, the FDA requires a pooled analysis of independently
adjudicated major adverse cardiovascular events [which should
include cardiovascular death, non-fatal myocardial infarction (MI),
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and non-fatal stroke and can include other endpoints] across all rele-
vant trials to provide reassurance that there is no substantial excess
cardiovascular risk. Specifically, one seeks evidence that compared
with a placebo control group, the risk ratio estimate has an upper
95% confidence limit ,1.8. If the upper bound of the confidence
interval (CI) excludes 1.8 but includes 1.3, then a separate, prospect-
ive, post-marketing, randomized safety trial is required to rule out
such a 30% increase in risk. The guidance did not specifically include
heart failure hospitalization as a cardiovascular safety endpoint of
interest, despite prior studies linking certain drugs for diabetes mel-
litus (peroxisome proliferator-activated receptor gamma agonists)
with this adverse event.2,3 At the time the guidance was released,
the consequences of these requirements on diabetes drug develop-
ment was uncertain.4
Several clinical trials designed to meet this regulatory require-
ment have been reported.5– 9 During the 11th and 12th Global Car-
diovascular Clinical Trialists Forum held in Washington, D.C. in
December 2014 and 2015, lessons learned from these clinical trials
were discussed among a group of cardiovascular and endocrinology
clinical trialists, biostatisticians, National Institutes of Health scien-
tists, European and US regulators, and pharmaceutical industry
scientists. This paper describes the ongoing controversies in the
field and calls for stakeholders to re-evaluate the current approach
to diabetes drug development such that two key objectives can
be fulfilled: (i) effective and safe drugs are available to patients and
(ii) patients can be informed about the magnitude and type of bene-
fit (e.g. morbidity/mortality, surrogate, or biomarker) offered by a
given therapy and potential risks that might offset these benefits.
Cardiovascular safety of therapies
for diabetes mellitus
Origin of the controversy
In the University Group Diabetes Programme (UGDP) conducted
in the early 1970s, albeit grossly underpowered, tolbutamide ap-
peared to be associated with an increased risk of cardiovascular
death compared with placebo.10,11 Some meta-analyses appear to
reinforce the idea that the cardiovascular profile of sulfonylureas
is worse than that observed for metformin and selective dipeptidyl
peptidase-4 (DPP-4) inhibitors,12,13 although these data are not
conclusive. In ADVANCE, 88% of patients in the intensive glucose
arm were treated with gliclazide MR compared with 57% treated
with another sulfonylurea in the standard therapy arm, and no evi-
dence of harm was observed.14 Historically, no regulatory measures
on therapies for type 2 diabetes were adopted (except a warning in
the labelling of sulfonylureas in the USA), until the rosiglitazone con-
troversies arose in 2007 (and subsequently in 2010). At that time,
emerging data with rosiglitazone introduced legitimate concerns re-
garding the benefit–risk equation for drugs used in the treatment of
type 2 diabetes. Specifically, when a drug is being used to improve a
biological marker (e.g. glycated haemoglobin), it is key to rule out
off-target effects that could change the benefit– risk of using a
drug for this purpose.
The regulatory reaction to the rosiglitazone case differed in the
USA and Europe. While the marketing authorization of rosiglita-
zone was suspended in the European Union, the FDA introduced
important labelling restrictions and warnings, but the drug remained
available by prescription. In contrast to the immediate regulatory ac-
tion, subsequent changes in regulatory approval standards were
substantially more demanding in the USA than in Europe. As previ-
ously noted, the FDA required systematic demonstration that the
potential increase in cardiovascular risk associated with a new
drug for the treatment of type 2 diabetes should not exceed 30%
compared with placebo or active control. This new standard virtu-
ally translated into the need to conduct large safety outcome studies
for all new therapies for diabetes mellitus (since diabetes drugs have
historically been approved on the basis of lowering glycated haemo-
globin). The European Medicines Agency (EMA) requirements were
less demanding, and the EMA guidance indicates that a long-term,
controlled outcome study with 18–24 months of follow-up is ex-
pected for drugs when an adverse cardiovascular effect is sus-
pected.15 The EMA does not pre-specify non-inferiority margins
that must be excluded by these analyses.15 From the EMA perspec-
tive, a new drug that improves glycaemic control should preferably
demonstrate a neutral or beneficial effect on parameters associated
with cardiovascular risk.15
Substantial controversy remains in the field about this regulatory
approach. Some worry that the policy to rule out a 95% upper
bound of the hazard ratio of 1.3 for cardiovascular harm (with a pre-
sumed hazard ratio of 1.0) is overly demanding and exceeds what
should be required for approval. However, others view it as not un-
usually demanding, since the requirement provides confidence with
P in the range of 0.05 (not a very rigorous standard) that there is not
a 30% excess in cardiovascular morbidity or mortality associated
with a drug used to improve a biomarker (i.e. glycated haemoglobin)
or slow the progression of clinically important but not immediately
life-threatening conditions (e.g. retinopathy, neuropathy, nephro-
pathy). Counter to the position that the standard is too rigorous,
one could argue that such a standard is inadequate in the face of
no obvious benefit on hard mortality or morbidity outcomes and
that approval should be based on efficacy on hard outcomes rather
than the current approach (i.e. approval based on improvements
in glycated haemoglobin and demonstration of no excess cardiovas-
cular risk).
What do the evolving data indicate?
Finalized and ongoing trials aiming to show cardiovascular safety of
new therapies for type 2 diabetes have now enrolled hundreds
of thousands of patients.4,16,17 In addition, many pooled analyses
of short- and medium-term trials have been conducted.18–22
Saxagliptin Assessment of Vascular Outcomes Recorded in Pa-
tients with Diabetes Mellitus—Thrombolysis in Myocardial
Infarction-53 (SAVOR-TIMI-53) and Examination of Cardiovascular
Outcomes with Alogliptin (EXAMINE) produced consistent find-
ings of no major harm but no cardiovascular benefit for these
DPP-4 inhibitors.5,6 In the Trial Evaluating Cardiovascular Out-
comes with Sitagliptin (TECOS), the DPP-4 inhibitor sitagliptin
was non-inferior to placebo for the primary composite endpoint
(cardiovascular death, non-fatal MI, non-fatal stroke, or hospitaliza-
tion for unstable angina, HR 0.98, 95% CI 0.88–1.09, P, 0.001).7
Heart failure hospitalization rates were not different between
groups (HR 1.00, 95% CI 0.83–1.20, P ¼ 0.98).7 The GLP-1 recep-
tor agonist lixisenatide was non-inferior (but not superior) to
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placebo for the primary composite outcome of cardiovascular
death, non-fatal MI, non-fatal stroke, or hospitalization for unstable
angina in the Evaluation of Lixisenatide in Acute Coronary Syn-
drome (ELIXA) study.9 The patient population in ELIXA was re-
markably similar to EXAMINE. There was no evidence of an
increased risk in heart failure events.9 The selective sodium glucose
cotransporter 2 inhibitor empagliflozin reduced the primary com-
posite of cardiovascular death, non-fatal MI, or non-fatal stroke
compared with placebo in the EMPA-REG OUTCOME trial, which
included patients with type 2 diabetes mellitus and established car-
diovascular disease (12.1 vs. 10.5%, HR 0.86, 95% CI 0.74–0.99, P,
0.001 non-inferiority, P ¼ 0.04 superiority).8 In addition,
meta-analyses of exenatide,18,22 liraglutide,19,22 sitagliptin,20,23 – 25
vildagliptin,21,23 – 25 and saxagliptin23 – 25 have shown no evidence
of harm (but with much less exposure than the large cardiovascular
outcome trials). Finally, the FDA has recently removed most of ro-
siglitazone’s cardiovascular harm labelling and dispensing restric-
tions as a result of further internal and external re-evaluation of
the data with independent event adjudication.26 To date, no new
sound adverse cardiovascular safety signal has arisen from these
analyses, and there is now evidence of benefit from the study with
empagliflozin. Altogether, these data raise the question of what
quantity and quality of evidence is sufficient to provide reasonable
assurance to regulatory authorities that cardiovascular safety is
not compromised, and whether it remains adequate to expend re-
sources to rule out harm instead of evaluating efficacy.
Time to rethink the policy? Issues
for reflection
A legitimate question is whether a continued focus on safety in lieu
of efficacy on clinical outcomes is appropriate. The relevance of this
question is not limited to the treatment of diabetes. For example,
cardiovascular outcome trials to rule out excess cardiovascular
risk of new anti-obesity drugs27,28 and gout29 have also been man-
dated by the FDA and are under consideration by the EMA. The re-
quirement has also led to some quandaries, such as premature
disclosure of interim study results. The sponsor of the 9000-patient
Light Trial (NCT01601704), designed to study the cardiovascular
safety of the obesity drug buproprion–naltrexone, prematurely
disclosed the study’s interim results (despite strict data disclosure
agreements), which led to subsequent appropriate, though un-
fortunate, halting of the study by the trial’s executive steering
committee.30
Hardening regulatory policies may be fully justified when based
on sound knowledge, but applying indiscriminate policies may easily
fall in the category of overregulation. Since all drugs have the poten-
tial for adverse outcomes, it is key to determine what level of risk
(i.e. unacceptable harm) and what degree of certainty patients and
providers are willing to accept to achieve the benefits associated
with improved glycaemic control if no specific cardiovascular out-
come benefits on efficacy endpoints are shown. Currently, with
the exception of data suggesting that some sulfonylureas may per-
form worse in terms of cardiovascular outcome than other classes
of diabetes drugs,10 – 13 the accumulated evidence appears to indi-
cate that the cardiovascular safety of agents for the treatment of
type 2 diabetes is not sufficiently concerning to justify a systematic
requirement of cardiovascular safety outcome studies for all drugs.
What about cardiovascular efficacy
outcome studies?
Since cardiovascular disease is the leading cause of death and disabil-
ity in patients with type 2 diabetes, the appropriate emphasis and re-
sources should be shifted to proving efficacy rather than ruling out
harm. The EMPA-REG OUTCOME study provides support for the
position that clinical trials should aim to assess efficacy on hard out-
comes.8 One key question is whether the trials have been optimally
designed to detect cardiovascular benefit if it exists. The most re-
cent studies, SAVOR-TIMI-53, EXAMINE, ELIXA, TECOS, and
EMPA-REG OUTCOME enrolled patients with known cardiovascu-
lar disease, at high risk of cardiovascular disease, or post-acute cor-
onary syndrome.5 –9 This approach satisfied the requirements of the
FDA guidance, which stipulates that Phases 2 and 3 programmes
should include patients at higher risk of cardiovascular events (e.g.
advanced disease, elderly, impaired renal function). Another intent
was to accrue a population with a sufficiently high event rate to
maintain an achievable sample size and a reasonable duration of
treatment exposure and follow-up. From the standpoint of cardio-
vascular safety, this population would be the most likely to demon-
strate adverse effects if they existed. These high-risk patients might
also be the least likely to show benefit on a cardiovascular endpoint,
if the advanced presence of existing disease, risk factors, or long-
standing diabetes is no longer modifiable by small reductions in
glycated haemoglobin (,0.5% in SAVOR-TIMI-53, EXAMINE, TE-
COS, and EMPA-REG OUTCOME), unless the drug exerts a posi-
tive cardiovascular effect that is independent from glycaemic control
(e.g. favourable effects of empagliflozin on weight loss, blood pres-
sure, vascular markers, visceral adiposity, albuminuria, and plasma
urate8 or potential cardioprotective effects of incretin-based
hormones).5,6,14,31,32 Whether one or a combination of properties
explains the positive effect of empagliflozin in EMPA-REG OUT-
COME is unknown, but it is unlikely to be related solely to improved
glycaemic control since the changes in glycated haemoglobin were
small. The neutral findings of other trials also suggest a unique effect
of empagliflozin separate from its ability to lower serum glucose.
It is plausible that a primary prevention population of patients
with type 2 diabetes with extended follow-up (.10 years)33 could
be expected to demonstrate efficacy on cardiovascular endpoints, if
one exists (e.g. EXSCEL, www.clinicaltrials.gov, NCT 01144338
with planned follow-up of up to 7.5 years34). Unfortunately, this ap-
proach would not be generally feasible in the current climate. It
would require a shift in other regulations to be successful, such as
providing longer patent protection35 to companies willing to com-
mit to a long-term drug development programme.
When a safety outcome study may be
necessary?
Clearly, every drug for the treatment of diabetes within a class or
group is different and has the potential for ancillary properties
that might affect risk. Regulatory requirements need to be tailored
to individual drugs and individual new chemical entities. Decisions
on the need for safety outcome studies should be made on an
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individual basis, after careful scrutiny of a safety database sufficiently
sized and prospectively designed in terms of number of patients,
minimum follow-up, population at risk, and safety endpoints of
interest.36
The focus of the study should also vary depending on the safety
concern arising. For example, it is likely that the relevance of drugs
for the treatment of type 2 diabetes as triggers of worsening heart
failure37 – 39 may have been underestimated in the past, while the
weight of atherogenic and/or prothrombotic disease has been over-
emphasized. The FDA Guidance document states that the cardio-
vascular endpoints of interest are ‘cardiovascular mortality, MI,
and stroke, and can include hospitalization for acute coronary syn-
drome (ACS), urgent revascularization procedures, and possibly
other endpoints’.1 But, with the novel agents for type 2 diabetes, ex-
clusive reliance on such endpoints may be inadequate to fully char-
acterize cardiovascular safety. For example, modulation of incretins
and their associated catabolic enzymes may impact myocardial func-
tion or regulation.40 – 42 B-type natriuretic peptide (BNP) is a sub-
strate to DPP-4, and it cleaves the physiologically active form of
BNP (1–32) to BNP (3–32), which may impact plasma cGMP and
the effect of BNP on diuresis, natriuresis, and vasodilation.43,44
This field is evolving, and it remains unclear how much DPP-4
may affect the pathophysiology of natriuretic peptides in heart fail-
ure, what influence DPP-4 inhibitors may have on BNP, and how
heart failure progression and clinical outcomes may be affected.43
The existing evidence from SAVOR-TIMI-53 and EXAMINE do
not show alterations in BNP or NT-pro-BNP for either of the drugs
compared with placebo.37– 39
This uncertainty underscores the need to individualize safety as-
sessments to specific drugs. The trials community has had difficulty
interpreting cardiovascular safety in the context of small, but appar-
ently significant, increases in heart failure hospitalization risk37,38
when there is no increase in MI, stroke, and cardiovascular death.
Based on the totality of evidence, it is probable that the increased
risk of heart failure hospitalizations observed in SAVOR-TIMI-53
was due to random noise, although the findings have recently led
the FDA to add warnings about heart failure risk to the labels of sax-
agliptin and alogliptin.45 In order to elucidate and interpret the con-
cern about re-hospitalization for HF with DPP-4 inhibitors, further
heterogeneity testing across the three trials (SAVOR-TIMI-53,
EXAMINE, TECOS) needs to be conducted, and this work is
ongoing.
Unfortunately, because the FDA guidance does not specifically
list heart failure among the endpoints of interest, few studies have
pre-specified heart failure as a primary or secondary endpoint.4,17,46
Heart failure events occur with similar frequency as other major ad-
verse cardiovascular events in clinical trials of patients with type 2
diabetes and elevated cardiovascular risk,47 occurring second to
MI and at a greater frequency than stroke in the placebo arms of
SAVOR-TIMI-53, EXAMINE, and TECOS.5 –7 Heart failure is ‘a car-
diovascular outcome in diabetes that can no longer be ignored’.46
Therefore, when a cardiovascular safety trial is deemed necessary,
depending on the safety signals detected in earlier phases of devel-
opment, heart failure should be assessed.46 Whether it should be a
stand-alone co-primary endpoint, a component of the primary com-
posite endpoint, or a key secondary endpoint depends on the study
population, the drug’s mechanism of action, and possibly other
factors. Assessment of patients’ cardiac function at baseline is also
useful to aid in the interpretation of results.
Conclusions
The consistency of evidence generated since the implementation of
the FDA guidance on assessing cardiovascular safety of diabetes
drugs raises the question of whether cardiovascular safety outcome
studies remain necessary for all new diabetes drugs, and whether in-
stead, approval should be based on a demonstration of efficacy on
cardiovascular outcomes. If improvement in glycated haemoglobin
continues to be accepted for approval, a more tailored approach
might now be appropriate, where the need for cardiovascular out-
come studies would be determined by regulators for each individual
drug based on its mechanism of action, pre-clinical or Phases 1 and 2
data, and the safety database. Only requiring cardiovascular out-
come safety trials when there is suspicion or a signal of an adverse
effect seems reasonable given the number of recent studies that
have demonstrated non-inferiority and the resources and time in-
volved in conducting these large-scale trials.36 A chance always ex-
ists that a drug will have an adverse effect that remains undetected
until it is widely used after approval; however, the magnitude of this
chance must be weighed against the burden of many thousands of
subjects who participate in these trials and the resources expended
to conduct the trials when effectiveness on important clinical events
is not the primary objective.
The long-term impact of therapies for type 2 diabetes on certain
cardiovascular morbidities that are relevant for patients is still not
definitively established. Thus, if a tailored approach to conducting
cardiovascular safety outcome studies were adopted, resources
could be shifted away from conducting cardiovascular safety out-
come trials in drugs where the suspicion for harm is low, towards
conducting trials designed to find effective therapies for improving
survival and reducing cardiovascular disease-related morbidity
over the long term. The recent findings of EMPA-REG OUTCOME
should reinvigorate interest in cardiovascular efficacy outcome
studies.
It is the responsibility of investigators, sponsors, and regulators to
ensure that the approval and use of new drugs for patients with in-
creased cardiovascular risk occurs under conditions of appropriate
safety and effectiveness, but it is also our responsibility to avoid in-
stituting unnecessary hurdles that may compromise access to useful
drugs and threaten the sustainability of health systems. The informa-
tion currently available is considered sufficient to revisit the debate
for new therapies to treat type 2 diabetes mellitus, where patients,
industry, regulators, and academia can openly discuss what certain-
ties are needed and how much uncertainty can be accepted.
Acknowledgements
The authors acknowledge and appreciate Michel Marre, Henry
Black, Blai Coll, Wesley Day, Kristina Dunder, David Gordon, Peter
Held, Dayi Hu, Christoph Koenen, Alfonso Perez, Beth Anne Piper,
and Harald Schmidt for their participation and insights provided
during the discussion of this topic at the Cardiovascular Clinical
Trialists meetings.
Assessing CV risk of new drugs for diabetes 203







This work was generated from discussions during the 10th–12th
Global Cardiovascular Clinical Trialists Forum held in Paris, France in
December 2013 and Washington D.C. in December 2014 and 2015.
Cardiovascular Clinical Trialists Forum was organized by the Clinical
Investigation Center Institut national de la sante et de la recherche
medicale (INSERM), Centres Hospitaliers Universitaires (CHU), and
University of Lorraine, France and funded by an unrestricted educational
grant from Association de Recherche et d’Information en Cardiologie, a
non-profit educational organization, in Nancy, France. Association de
Recherche et d’Information en Cardiologie had no involvement in the
preparation, review, or approval of the manuscript for publication.
Conflict of interest: F.Z.: grant support from Roche Diagnostics; per-
sonal fees from Air Liquide, Bayer, Biomerieux, Biotronik, Boston Scien-
tific, CVRx, Janssen, Novartis, Pfizer, Resmed, Sanofi, Servier, St Jude
Medical, Takeda, Mitsubishi, and CardioRenal Diagnostics. W.G.S.: con-
sultant to Overcome (travel expense reimbursement to attend Cardio-
vascular Clinical Trialists 2013 and professional time related to
preparation of this paper); consultant to Covis Pharmaceuticals and Re-
lypsa. J.T.: advisory boards and/or speaker’s bureau for Menarini. G.L.B.:
consultant to Takeda, AbbVie, CVRx, Janssen, Eli Lilly/Boehringer-
Ingelheim, Medtronic, AstraZeneca, Novartis, GSK, Bayer, and Daichi-
Sankyo. J.S.B.: consultant to Cardiorentis, Takeda USA, Pfizer, Novartis,
ARMGO, Amgen, Servier, Boehringer-Ingelheim, and Celladon; stock in
Roche, Abbott, Gilead, and BioMARIN. W.K.: honoraria for lectures
from AstraZeneca, Novartis, MSD, and Amgen; consulting fees from
Roche, dia Dexus, Novartis, Pfizer, The Medicines Company, Genzyme,
Servier, Amgen, AstraZeneca, MSD, and Sanderling Ventures; research
contracts from Roche Diagnostics, Beckmann, Singulex, and Abbott.
S.K.: full-time employee of Takeda Pharmaceuticals International.
O.M.: research grant support through Hadassah University Hospital
from Novo Nordisk; speaker’s bureau for AstraZeneca, Bristol-Myers
Squibb, Novo Nordisk, Eli Lilly, Sanofi, Novartis, and MSD; advisory
board for AstraZeneca, Bristol-Myers Squibb, Novo Nordisk, Eli Lilly,
Sanofi, and Novartis; grants paid to institution as a study physician by As-
traZeneca and Bristol-Myers Squibb. S.P.: DSMB member for TECOS,
EXSCEL, and ACE trials; steering committee member for the LEADER
trial and DISCOVER registry. A.J.S.: honoraria for lectures and consult-
ing fees from AstraZeneca, BMS, Boehringer-Ingelheim, Eli Lilly, Janssen,
MSD, Novartis, NovoNordisk, Sanofi, and Takeda; unrestricted re-
search grant from NovoNordisk. H.S.: unrestricted research grants
from AstraZeneca, Bo¨hringer Ingelheim, and Takeda; participation in ad-
visory boards of AstraZeneca, Bo¨hringer Ingelheim, Eli Lilly, MSD, No-
vartis, NovoNordisk, and Sanofi. C.I.S.: employee of AstraZeneca.
W.B.W.: safety consultant (endpoint committees, data safety monitor-
ing committees, and steering committees only) for AstraZeneca, Chel-
sea Therapeutics, Forest Research Institute, Roche, Inc., Teva, Inc., and
Takeda Development Center; research funding from exclusively
National Institutes of Health, Bethesda, MD, USA. G.C.: consultant to
Takeda, Bayer, Novartis, AstraZeneca, Eli Lilly, Almirall, Ferrer, Hospira,
Celtrion, and Pfizer.
References
1. Food and Drug Administration. Guidance for industry diabetes mellitus—evaluating
cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. http://
www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/
guidances/UCM071627.pdf (last updated: 2008; accessed: 24 July 2015).
2. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse
cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005;294:
2581–2586.
3. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and
death from cardiovascular causes. N Engl J Med 2007;356:2457–2471.
4. Zannad F, Stough WG, Pocock SJ, Sleight P, Cushman WC, Cleland JG, McMurray JJ,
Lonn E, Geller NL, Wedel H, Abadie E, Alonso-Garcia A, Pitt B. Diabetes clinical
trials: helped or hindered by the current shift in regulatory requirements? Eur Heart
J 2012;33:1049–1057.
5. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT,
Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F. Alogliptin after
acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:
1327–1335.
6. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P,
Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR,
Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I. Saxagliptin and cardiovascular
outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:
1317–1326.
7. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R,
Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E,
Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR. Effect of sitaglip-
tin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:
232–242.
8. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M,
Devins T, Johansen O, Woerle HJ, Broedl U, Inzucchi SE. Empagliflozin, cardiovas-
cular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:
2117–2128.
9. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV, Lawson FC,
Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC,
Solomon SD, Tardif JC. Lixisenatide in patients with type 2 diabetes and acute cor-
onary syndrome. N Engl J Med 2015;373:2247–2257.
10. Goldner MG, Knatterud GL, Prout TE. Effects of hypoglycemic agents on vascular
complications in patients with adult-onset diabetes. 3. Clinical implications of
UGDP results. JAMA 1971;218:1400–1410.
11. Meinert CL, Knatterud GL, Prout TE, Klimt CR. A study of the effects of hypogly-
cemic agents on vascular complications in patients with adult-onset diabetes. II.
Mortality results. Diabetes 1970;19(Suppl.):830.
12. Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: a
meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013;15:938–953.
13. Phung OJ, Schwartzman E, Allen RW, Engel SS, Rajpathak SN. Sulphonylureas and
risk of cardiovascular disease: systematic review and meta-analysis. Diabet Med
2013;30:1160–1171.
14. Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, Arima H, Monaghan H,
Joshi R, Colagiuri S, Cooper ME, Glasziou P, Grobbee D, Hamet P, Harrap S,
Heller S, Lisheng L, Mancia G, Marre M, Matthews DR, Mogensen CE,
Perkovic V, Poulter N, Rodgers A, Williams B, MacMahon S, Patel A,
Woodward M. Follow-up of blood-pressure lowering and glucose control in
type 2 diabetes. N Engl J Med 2014;371:1392–1406.
15. European Medicines Agency Committee for Medicinal Products for Human Use
(CHMP). Guideline on clinical investigation of medicinal products in the treatment
or prevention of diabetes mellitus. http://www.ema.europa.eu/docs/en_GB/
document_library/Scientific_guideline/2012/06/WC500129256.pdf (last
updated: 14 May 2012; accessed: 24 March 2015).
16. Bethel MA, Sourij H. Impact of FDA guidance for developing diabetes drugs on trial
design: from policy to practice. Curr Cardiol Rep 2012;14:59–69.
17. Holman RR, Sourij H, Califf RM. Cardiovascular outcome trials of glucose-lowering
drugs or strategies in type 2 diabetes. Lancet 2014;383:2008–2017.
18. Ratner R, Han J, Nicewarner D, Yushmanova I, Hoogwerf BJ, Shen L. Cardiovascu-
lar safety of exenatide BID: an integrated analysis from controlled clinical trials in
participants with type 2 diabetes. Cardiovasc Diabetol 2011;10:22.
19. Marso SP, Lindsey JB, Stolker JM, House JA, Martinez RG, Kennedy KF, Jensen TM,
Buse JB. Cardiovascular safety of liraglutide assessed in a patient-level pooled ana-
lysis of phase 2–3 liraglutide clinical development studies. Diab Vasc Dis Res 2011;8:
237–240.
20. Williams-Herman D, Engel SS, Round E, Johnson J, Golm GT, Guo H, Musser BJ,
Davies MJ, Kaufman KD, Goldstein BJ. Safety and tolerability of sitagliptin in clinical
studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC
Endocr Disord 2010;10:7.
21. Schweizer A, Dejager S, Foley JE, Couturier A, Ligueros-Saylan M, Kothny W. As-
sessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudi-
cated events from a large Phase III type 2 diabetes population. Diabetes Obes
Metab 2010;12:485–494.
22. Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E. Effects of glucagon-like
peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized
clinical trials. Diabetes Obes Metab 2014;16:38–47.
23. Patil HR, Al Badarin FJ, Al Shami HA, Bhatti SK, Lavie CJ, Bell DS, O’Keefe JH.
Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk
in type 2 diabetes mellitus. Am J Cardiol 2012;110:826–833.
F. Zannad et al.204






24. Monami M, Ahren B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors
and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes
Obes Metab 2013;15:112–120.
25. Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and heart
failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2014;
24:689–697.
26. Mahaffey KW, Hafley G, Dickerson S, Burns S, Tourt-Uhlig S, White J, Newby LK,
Komajda M, McMurray J, Bigelow R, Home PD, Lopes RD. Results of a reevaluation
of cardiovascular outcomes in the RECORD trial. Am Heart J 2013;166:240–249.
27. Hiatt WR, Goldfine AB, Kaul S. Cardiovascular risk assessment in the development
of new drugs for obesity. JAMA 2012;308:1099–1100.
28. European Medicines Agency. Concept paper on the need for revision of the guide-
lines of medical products used in weight control. http://ema.europa.eu/docs/
en_GB/document_library/scientific_guideline/2012/10/WC500133166.
pdf (last updated: 2012; accessed: 24 July 2015).
29. White WB, Chohan S, Dabholkar A, Hunt B, Jackson R. Cardiovascular safety of
febuxostat and allopurinol in patients with gout and cardiovascular comorbidities.
Am Heart J 2012;164:14–20.
30. O’Riordan M. LIGHT Stopped: Contrave CVD Safety Study Halted Following Pre-
mature Release of Data. http://www.medscape.com/viewarticle/844575#vp_1.
(last updated: 12 May 2015; accessed: 10 June 2015).
31. Mosenzon O, Raz I. Potential cardiovascular effects of dipeptidyl peptidase-4 inhi-
bitors in patients with type 2 diabetes: current evidence and ongoing trials. Eur
Heart J Suppl 2012;14:B22–B29.
32. Scheen AJ, Charbonnel B. Effects of glucose-lowering agents on vascular outcomes
in type 2 diabetes: a critical reappraisal. Diabetes Metab 2014;40:176–185.
33. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up
of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:
1577–1589.
34. Holman RR, Bethel MA, George J, Sourij H, Doran Z, Keenan J, Khurmi NS,
Mentz RJ, Oulhaj A, Buse JB, Chan JC, Iqbal N, Kundu S, Maggioni AP, Marso SP,
Ohman P, Pencina MJ, Poulter N, Porter LE, Ramachandran A, Zinman B,
Hernandez AF. Rationale and design of the EXenatide Study of Cardiovascular
Event Lowering (EXSCEL) trial. Am Heart J 2016;174:103–110.
35. Cleland JG, Atkin SL. Thiazolidinediones, deadly sins, surrogates, and elephants.
Lancet 2007;370:1103–1104.
36. Sager PT, Seltzer J, Turner JR, Anderson JL, Hiatt WR, Kowey P, Prochaska JJ,
Stockbridge N, White WB. Cardiovascular safety outcome trials: a meeting report
from the Cardiac Safety Research Consortium. Am Heart J 2015;169:486–495.
37. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, Udell JA,
Mosenzon O, Im K, Umez-Eronini AA, Pollack PS, Hirshberg B, Frederich R,
Lewis BS, McGuire DK, Davidson J, Steg PG, Bhatt DL. Heart failure, saxagliptin
and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.
Circulation 2014;130:1579–1588.
38. Standl E. Saxagliptin, alogliptin, and cardiovascular outcomes. N Engl J Med 2014;
370:483.
39. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR,
Mehta CR, Kupfer S, Wilson C, Lam H, White WB. Heart failure and mortality
outcomes in patients with type 2 diabetes taking alogliptin versus placebo in
EXAMINE: a multicentre, randomised, double-blind trial. Lancet 2015;385:
2067–2076.
40. Khan MA, Deaton C, Rutter MK, Neyses L, Mamas MA. Incretins as a novel thera-
peutic strategy in patients with diabetes and heart failure. Heart Fail Rev 2013;18:
141–148.
41. Oyama J, Node K. Incretin therapy and heart failure. Circ J 2014;78:819–824.
42. Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res
2014;114:1788–1803.
43. Shannon RP, Angeli FS. Beyond glucose: cardiovascular effects of incretins and di-
peptidyl peptidase-4 substrates. Eur Heart J Suppl 2012;14:B14–B21.
44. Boerrigter G, Costello-Boerrigter LC, Harty GJ, Lapp H, Burnett JC Jr.
Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am J
Physiol Regul Integr Comp Physiol 2007;292:R897–R901.
45. U.S. Food and Drug Administration. FDA drug safety communication: FDA
adds warnings about heart failure risk to labels of type 2 diabetes medicines con-
taining saxagliptin and alogliptin. http://www.fda.gov/Drugs/DrugSafety/
ucm486096.htm (last updated: 5 April 2016; accessed: 18 April 2016).
46. McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: a cardiovascular
outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol 2014;
2:843–851.
47. Vaur L, Gueret P, Lievre M, Chabaud S, Passa P. Development of congestive heart
failure in type 2 diabetic patients with microalbuminuria or proteinuria: observa-
tions from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular
Events and Ramipril) study. Diabetes Care 2003;26:855–860.
Assessing CV risk of new drugs for diabetes 205
 by guest on July 20, 2016
http://ehjcvp.oxfordjournals.org/
D
ow
nloaded from
 
